A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT06888115
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 104
- Registration Number
- NCT06573528
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 80
- Registration Number
- NCT06485245
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Study of [14C]CS0159 in China Healthy Subjects
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 6
- Registration Number
- NCT06098027
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
- Conditions
- Primary Biliary Cholangitis (PBC)
- Interventions
- Drug: 2mg CS0159Drug: Placebo
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 75
- Registration Number
- NCT05896124
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Beijing Friendship Hospital, Captail Medcial University, Beijing, Beijing, China
🇨🇳Beijing Youan Hostital, Captial Medical University, Beijing, Beijing, China
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 50
- Registration Number
- NCT05896137
- Locations
- 🇨🇳
The First Affiliated Hospital,Zhejiang University School of Medicine, HangZhou, Zhejiang, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 36
- Registration Number
- NCT05624294
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Drug: CS0159 (Linafexor)
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 99
- Registration Number
- NCT05591079
- Locations
- 🇺🇸
Floridian Clinical Research, LLC - Miami Lakes, Miami Lakes, Florida, United States
🇺🇸Florida Research Institute, Lakewood, Florida, United States
🇺🇸San Marcus Research Clinic, Inc - Miami, Miami, Florida, United States
Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 79
- Registration Number
- NCT05082779
- Locations
- 🇺🇸
Labcorp Clinical Research Unit, Inc., Daytona Beach, Florida, United States